These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33012106)

  • 21. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
    Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
    Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
    McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L
    Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting.
    Gourzoulidis G; Stefanou G; Economou M; Vakalopoulou S; Filippidis G; Soultatis G; Kontos D; Tzima S; Ntemousis F; Fassa A; Kourlaba G
    Clin Drug Investig; 2022 Jan; 42(1):75-85. PubMed ID: 34874542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel.
    Escuriola-Ettingshausen C; Auerswald G; Königs C; Kurnik K; Scholz U; Klamroth R; Oldenburg J
    Haemophilia; 2021 May; 27(3):e305-e313. PubMed ID: 32937002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
    Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
    Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
    Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
    Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of the budgetary impact of an emicizumab therapy introduction for patients with severe haemophilia A without inhibitor].
    Oka G; Pieragostini R; Roussel-Robert V; Paubel P; Degrassat-Theas A; Lopez I
    Ann Pharm Fr; 2023 May; 81(3):529-537. PubMed ID: 36375527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Holstein K; Le Quellec S; Klamroth R; Batorova A; Holme PA; Jiménez-Yuste V; Astermark J
    Haemophilia; 2022 Mar; 28(2):215-222. PubMed ID: 34918839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.
    Valentino LA; Khair K
    Expert Rev Hematol; 2020 Jul; 13(7):731-743. PubMed ID: 32573295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
    Polack B; Trossaërt M; Cousin M; Baffert S; Pruvot A; Godard C
    Haemophilia; 2021 Jan; 27(1):e1-e11. PubMed ID: 33210412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A; Desborough MJR; Raza-Burton S; Taylor S; Wilkinson A; Hall GW; Shapiro S; Curry N
    Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.